arrow
J

Jacob Sands

Dana-Farber Cancer Institute
H指数:29
被引数:4,119

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer

TROP2的归一化膜比作为datopotamab deruxtecan在非小细胞肺癌中预测临床结局的指标

2026-11-110
OAAI
Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer

维布司妥利单抗与帕博利珠单抗联合化疗作为广泛期小细胞肺癌的一线治疗方案

2026-10-200
OAAI
Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025

肺癌护理中的当前挑战与新兴治疗策略:Bridging the Gaps 2025的见解

Cancer
IF5.1
2026-09-290
PRE
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer

AZD2811在复发/难治性小细胞肺癌的I期剂量扩展研究中通过生物标志物分析进行疗效监测

2026-04-030
OAAI
Small Cell Lung Cancer, Version 2.2026 Featured Updates to the NCCN Guidelines

小细胞肺癌,2026年第2版NCCN指南特色更新

2026-01-010
PRE
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024

肺癌管理临床策略:2024年弥合差距肺癌共识会议的建议

Cancer
IF5.1
2025-08-260
PRE
US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan

美国专家德尔菲共识:datopotamab deruxtecan治疗患者的口腔炎预防与管理

2025-08-050
OA
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Datopotamab Deruxtecan在EGFR突变非小细胞肺癌患者中的合并分析

2025-06-120
OAAI
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer
CANCER
IF5.1
2025-01-280
OAAI
Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05

达波替安德鲁克坦(Dato-DXd)在既往治疗过的EGFR突变型晚期非小细胞肺癌(NSCLC)患者(pts)中的有效性与安全性:TROPION-Lung01和TROPION-Lung05的合并分析

2024-12-012
PRE
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer
2024-11-120
OAAI
SKYBRIDGE study: An open-label, multicenter, dose escalation and dose expansion phase I/II study of PT217 as a monotherapy and in combination with an atezolizumab, in patients with SCLC, LCNEC and EP-NEC known to express DLL3

SKYBRIDGE研究:一项开放标签、多中心、剂量递增和剂量扩展的I/II期研究,评估PT217作为单药治疗以及联合atezolizumab在已知表达DLL3的SCLC、LCNEC和EP-NEC患者中的应用。

2024-09-010
PRE
Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01

Datopotamab deruxtecan (Dato-DXd) 与多西他赛 (DTX) 在伴有脑转移 (mets) 的晚期非鳞状 (NSQ) 非小细胞肺癌 (NSCLC) 患者中的比较:TROPION-Lung01 研究结果

2024-09-010
PRE
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan

与datopotamab deruxtecan相关的特别关注的不良事件的临床管理,监测和预防

2024-04-016
OAAI